A combination of Bcl-2 and YAP inhibitors demonstrated a synergistic effect, substantially reducing tumor area and invasiveness in Nf2-KO S1M cells (Fig. 5, O-Q), emphasizing the potential therapeutic value of this combination in NF2 deficient GC. Here, BCL2 is linked to gastric cancer.